

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request: cder_mpl1r_wp207

Request ID: cder_mpl1r_wp207_nsdv_v01

Request Description: In this report we examined counts of individuals who received Sinuva or Propel, both of which are mometasone furoate (MF) sinus stents, for the treatment of nasal polyps in the Sentinel Distributed Database (SDD). Additionally, we examined these individuals further on whether or not they also had a record indicating the presence of glaucoma or cataracts in the six months prior to receiving the Sinuva MF sinus stent.

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 10.1.1

Data Source: We distributed this query to 14 Sentinel Data Partners on July 2, 2021. The study period included data from January 1, 2016 through April 30, 2021. Please see Appendix A for a list of dates of available data for each Data Partner.

Study Design: We identified individuals with incident use of Sinuva or Propel MF sinus stents in cohorts which included patients of all ages. All individuals were required to have a record of nasal polyps within the six months prior to index, and depending on the cohort, individuals were excluded based on records for glaucoma, cataracts, or prior receipt of MF sinus stents. Counts were stratified by age, sex, race, Hispanic origin, and year. The query then characterized dispensing patterns by examining cumulative exposure episode durations, first exposure episode durations, all exposure episode durations, days supplied per dispensing, and lengths of gaps between episodes. This is a Type 5 analysis in the Query Request Package (QRP) documentation.

Exposure(s) of Interest: The exposures of interest were defined using both dispensing data and National Drug Codes (NDCs), as well as Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), and Healthcare Common Procedure Coding System, Level II (HCPCS) codes. Please refer to Appendix B for a list of CPT-3, CPT-4, and HCPCS codes used to define exposures in this request. Refer to Appendix C for a list of generic and brand names of medical products used to define exposures in this request.

Cohort Eligibility Criteria: We defined index date for each patient as the date of the first dispensing of a MF stent of interest. We required members to be enrolled in health plans with medical and drug coverage in the 183 days prior to their index date in order to be included in the cohort; a gap in coverage of up to 45 days was allowed and treated as continuous enrollment. We created the following eight cohorts with the inclusion/exclusion criteria as described below:

1. Propel MF Sinus Stent single use cohort: Propel MF Sinus Stent dispensing and no evidence of a Propel or Sinuva MF Sinus Stent in the 183 days prior to the index dispensing
2. Sinuva MF single use cohort: Sinuva MF Sinus Stent dispensing and no evidence of a Propel or Sinuva MF Sinus Stent in the 183 days prior to the index dispensing
3. Sinuva MF single use and no Glaucoma cohort: Sinuva MF Sinus Stent dispensing and no evidence of either a Propel or Sinuva MF Sinus Stent or glaucoma in the 183 days prior to the index dispensing
4. Sinuva MF single use and no Cataracts cohort: Sinuva MF Sinus Stent dispensing and no evidence of either a Propel or Sinuva MF Sinus Stent or cataracts in the 183 days prior to the index dispensing
5. Sinuva MF single use incident on self cohort: Sinuva MF Sinus Stent dispensing and no evidence of a Sinuva MF Sinus Stent in the 183 days prior to the index dispensing
6. Sinuva MF single use incident on self and no Glaucoma cohort: Sinuva MF Sinus Stent dispensing and no evidence of a Sinuva MF Sinus Stent and glaucoma in the 183 days prior to the index dispensing
7. Sinuva MF single use incident on self and no Cataracts cohort: Sinuva MF Sinus Stent dispensing and no evidence of a Sinuva MF Sinus Stent and cataracts in the 183 days prior to the index dispensing
8. Sinuva MF Repeat Use cohort: Sinuva MF Sinus Stent dispensing (no additional cohort criteria applied)

The following age groups were included in the cohorts: 0-1, 2-4, 5-9, 10-14, 15-18, 19-21, 22-44, 45-64, 65-74, 75+ years. We also required evidence of nasal polyps in the 183 days (six months) prior to the index dispensing.

Overview for Request: cder_mpl1r_wp207

Please see Appendix D for a list of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) procedure and diagnosis codes used to define inclusion criteria in this request. See Appendix E for a list of CPT-3, CPT-4, HCPCS, ICD-9-CM, ICD-10-CM, and ICD-10-PCS codes used to define exclusion criteria in this request. See Appendix F for a list of generic and brand names of medical products used to define exclusion criteria in this request.

Limitations: Algorithms to define exposures, inclusion, and exclusion criteria are imperfect and may result in misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinelssystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

Table of contents

Glossary	List of Terms Found in this Report and their Definitions
Table 1a	Aggregate Baseline Table, Propel Mometasone Furoate (MF) Sinus Stent Single Use Cohort in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021
Table 1b	Aggregated Baseline Table, Sinuva Mometasone Furoate (MF) Repeat Use Cohort in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021
Table 1c	Aggregated Baseline Table, Sinuva Mometasone Furoate (MF) Single Use Cohort in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021
Table 1d	Aggregated Baseline Table, Sinuva Mometasone Furoate (MF) Single Use and No Cataracts Cohort in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021
Table 1e	Aggregated Baseline Table, Sinuva Mometasone Furoate (MF) Single Use and No Glaucoma Cohort in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021
Table 1f	Aggregated Baseline Table, Sinuva Mometasone Furoate (MF) Single Use Incident on Self Cohort in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021
Table 1g	Aggregated Baseline Table, Sinuva Mometasone Furoate (MF) Single Use Incident on Self and No Cataracts Cohort in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021
Table 1h	Aggregated Baseline Table, Sinuva Mometasone Furoate (MF) Single Use Incident on Self and No Glaucoma Cohort in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021
Table 2a	Descriptive Statistics of Cumulative Mometasone Furoate (MF) Sinus Stent Exposure Episode Duration in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days, Overall
Table 2b	Descriptive Statistics of Cumulative Mometasone Furoate (MF) Sinus Stent Exposure Episode Duration in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days, by Sex
Table 2c	Descriptive Statistics of Cumulative Mometasone Furoate (MF) Sinus Stent Exposure Episode Duration in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days, by Age Group (Years)
Table 3a	Descriptive Statistics of First Exposure to a Mometasone Furoate (MF) Sinus Stent in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, Episode Duration, in Days, Overall
Table 3b	Descriptive Statistics of First Exposure to a Mometasone Furoate (MF) Sinus Stent in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, Episode Duration, in Days, by Sex
Table 3c	Descriptive Statistics of First Exposure to a Mometasone Furoate (MF) Sinus Stent in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, Episode Duration, in Days, by Age Group (Years)
Table 4a	Descriptive Statistics of All Exposure Episode Durations to Mometasone Furoate (MF) Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days, Overall
Table 4b	Descriptive Statistics of All Exposure Episode Durations to Mometasone Furoate (MF) Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days, by Sex
Table 4c	Descriptive Statistics of All Exposure Episode Durations to Mometasone Furoate (MF) Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days, by Age Group (Years)
Table 5a	Descriptive Statistics of Days Supplied per Dispensing for Mometasone Furoate (MF) Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, Overall
Table 5b	Descriptive Statistics of Days Supplied per Dispensing for Mometasone Furoate (MF) Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, by Sex
Table 5c	Descriptive Statistics of Days Supplied per Dispensing for Mometasone Furoate (MF) Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, by Age Group (Years)
Table 6a	Descriptive Statistics of the Length of All Gaps between Treatment Episodes for Mometasone Furoate (MF) Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days
Table 6b	Descriptive Statistics of the Length of All Gaps between Treatment Episodes for Mometasone Furoate (MF) Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days, by

Table of contents

Table 6c Descriptive Statistics of the Length of All Gaps between Treatment Episodes for Mometasone Furoate (MF) Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days, by Age Group (Years)

Table 7 Counts of Reason for Censoring, All Episodes and First Episode of Mometasone Furoate (MF) Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021

Appendix A Dates of Available Data for Each Data Partner (DP) as of Query Distribution Date

Appendix B List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), and Healthcare Common Procedure Coding System, Level II (HCPCS) Procedure Codes Used to Define Exposures in this Request

Appendix C List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request

Appendix D List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Inclusion Criteria in this Request

Appendix E List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Appendix F List of Generic and Brand Names of Medical Products Used to Define Exclusion Criteria in this Request

Appendix G Specifications Defining Parameters in this Request

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Aggregate Baseline Table, Propel Mometasone Furoate (MF) Sinus Stent Single Use Cohort in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021

Characteristic¹	Number	
Number of unique patients	21,869	
Demographics		
Mean Age (Years)	60.6	13.5
Age (Years)	Number	Percent
0-1	*****	0.0%
2-4	*****	0.0%
5-9	51	0.2%
10-14	151	0.7%
15-18	248	1.1%
19-21	199	0.9%
22-44	3,560	16.3%
45-64	6,155	28.1%
65-74	7,497	34.3%
75+	3,997	18.3%
Sex		
Female	9,073	41.5%
Male	12,796	58.5%
Race ²		
American Indian or Alaska Native	47	0.2%
Asian	304	1.4%
Black or African American	1,031	4.7%
Native Hawaiian or Other Pacific Islander	21	0.1%
Unknown	8,091	37.0%
White	12,375	56.6%
Hispanic Origin	348	1.6%
Year		
2016	4,283	19.6%
2017	4,916	22.5%
2018	5,607	25.6%
2019	5,803	26.5%
2020	1,260	5.8%
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	16.3	12.7
Mean number of emergency room encounters (ED)	0.4	1.2
Mean number of inpatient hospital encounters (IP)	0.1	0.5
Mean number of non-acute institutional encounters (IS)	0.0	0.2
Mean number of other ambulatory encounters (OA)	3.1	6.5
Mean number of filled prescriptions	19.9	16.8
Mean number of generics	9.2	5.5
Mean number of unique drug classes	8.5	4.9

¹All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort

²In the SDD, race information is not well populated and there are substantial proportions of "unknown" race and Hispanic indicator values. Specifically, two commercial Data Partners do not provide any race or ethnicity data.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1b. Aggregated Baseline Table, Sinuva Mometasone Furoate (MF) Repeat Use Cohort in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021

Characteristic¹	Number	
Number of unique patients	406	
Demographics	Mean	Standard Deviation
Mean Age (Years)	51.1	12.7
Age (Years)	Number	Percent
0-1	0	0.0%
2-4	0	0.0%
5-9	0	0.0%
10-14	*****	*****
15-18	*****	*****
19-21	*****	*****
22-44	131	32.3%
45-64	174	42.9%
65-74	67	16.5%
75+	22	5.4%
Sex		
Female	169	41.6%
Male	237	58.4%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	294	72.4%
White	101	24.9%
Hispanic Origin	*****	*****
Year		
2016	0	0.0%
2017	0	0.0%
2018	103	25.4%
2019	203	50.0%
2020	100	24.6%
Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters (AV)	13.0	9.1
Mean number of emergency room encounters (ED)	0.2	0.5
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.0
Mean number of other ambulatory encounters (OA)	1.7	2.8
Mean number of filled prescriptions	16.8	12.5
Mean number of generics	8.2	4.6
Mean number of unique drug classes	7.6	4.2

¹All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort

²In the SDD, race information is not well populated and there are substantial proportions of "unknown" race and Hispanic indicator values. Specifically, two commercial Data Partners do not provide any race or ethnicity data.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1c. Aggregated Baseline Table, Sinuva Mometasone Furoate (MF) Single Use Cohort in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021

Characteristic¹	Number	
Number of unique patients	366	
Demographics	Mean	Standard Deviation
Mean Age (Years)	51.5	12.6
Age (Years)	Number	Percent
0-1	0	0.0%
2-4	0	0.0%
5-9	0	0.0%
10-14	*****	*****
15-18	*****	*****
19-21	*****	*****
22-44	117	32.0%
45-64	156	42.6%
65-74	61	16.7%
75+	21	5.7%
Sex		
Female	146	39.9%
Male	220	60.1%
Race²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	264	72.1%
White	94	25.7%
Hispanic Origin	*****	*****
Year		
2016	0	0.0%
2017	0	0.0%
2018	88	24.0%
2019	187	51.1%
2020	91	24.9%
Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters (AV)	12.6	8.9
Mean number of emergency room encounters (ED)	0.1	0.4
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.0
Mean number of other ambulatory encounters (OA)	1.7	2.8
Mean number of filled prescriptions	16.1	12.2
Mean number of generics	8.0	4.5
Mean number of unique drug classes	7.4	4.1

¹All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort

²In the SDD, race information is not well populated and there are substantial proportions of "unknown" race and Hispanic indicator values. Specifically, two commercial Data Partners do not provide any race or ethnicity data.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1d. Aggregated Baseline Table, Sinuva Mometasone Furoate (MF) Single Use and No Cataracts Cohort in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021

Characteristic¹	Number	
Number of unique patients	270	
Demographics	Mean	Standard Deviation
Mean Age (Years)	50.1	12.7
Age (Years)	Number	Percent
0-1	0	0.0%
2-4	0	0.0%
5-9	0	0.0%
10-14	*****	*****
15-18	*****	*****
19-21	*****	*****
22-44	94	34.8%
45-64	119	44.1%
65-74	36	13.3%
75+	13	4.8%
Sex		
Female	108	40.0%
Male	162	60.0%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	202	74.8%
White	61	22.6%
Hispanic Origin	*****	*****
Year		
2016	0	0.0%
2017	0	0.0%
2018	68	25.2%
2019	143	53.0%
2020	59	21.9%
Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters (AV)	12.1	8.6
Mean number of emergency room encounters (ED)	0.2	0.5
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.0
Mean number of other ambulatory encounters (OA)	1.6	3.1
Mean number of filled prescriptions	15.8	11.2
Mean number of generics	7.9	4.5
Mean number of unique drug classes	7.3	4.0

¹All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort

²In the SDD, race information is not well populated and there are substantial proportions of "unknown" race and Hispanic indicator values. Specifically, two commercial Data Partners do not provide any race or ethnicity data.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1e. Aggregated Baseline Table, Sinuva Mometasone Furoate (MF) Single Use and No Glaucoma Cohort in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021

Characteristic¹	Number	
Number of unique patients	349	
Demographics	Mean	Standard Deviation
Mean Age (Years)	50.9	12.7
Age (Years)	Number	Percent
0-1	0	0.0%
2-4	0	0.0%
5-9	0	0.0%
10-14	*****	*****
15-18	*****	*****
19-21	*****	*****
22-44	117	33.5%
45-64	148	42.4%
65-74	52	14.9%
75+	21	6.0%
Sex		
Female	142	40.7%
Male	207	59.3%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	254	72.8%
White	87	24.9%
Hispanic Origin	*****	*****
Year		
2016	0	0.0%
2017	0	0.0%
2018	85	24.4%
2019	177	50.7%
2020	87	24.9%
Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters (AV)	12.5	8.9
Mean number of emergency room encounters (ED)	0.1	0.5
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.0
Mean number of other ambulatory encounters (OA)	1.6	2.9
Mean number of filled prescriptions	16.1	12.3
Mean number of generics	7.9	4.6
Mean number of unique drug classes	7.3	4.1

¹All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort

²In the SDD, race information is not well populated and there are substantial proportions of "unknown" race and Hispanic indicator values. Specifically, two commercial Data Partners do not provide any race or ethnicity data.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1f. Aggregated Baseline Table, Sinuva Mometasone Furoate (MF) Single Use Incident on Self Cohort in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021

Characteristic¹	Number	
Number of unique patients	403	
Demographics	Mean	Standard Deviation
Mean Age (Years)	51.1	12.7
Age (Years)	Number	Percent
0-1	0	0.0%
2-4	0	0.0%
5-9	0	0.0%
10-14	*****	*****
15-18	*****	*****
19-21	*****	*****
22-44	130	32.3%
45-64	173	42.9%
65-74	67	16.6%
75+	21	5.2%
Sex		
Female	167	41.4%
Male	236	58.6%
Race²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	292	72.5%
White	100	24.8%
Hispanic Origin	*****	*****
Year		
2016	0	0.0%
2017	0	0.0%
2018	102	25.3%
2019	202	50.1%
2020	99	24.6%
Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters (AV)	13.0	9.1
Mean number of emergency room encounters (ED)	0.2	0.5
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.0
Mean number of other ambulatory encounters (OA)	1.7	2.8
Mean number of filled prescriptions	16.8	12.5
Mean number of generics	8.2	4.6
Mean number of unique drug classes	7.6	4.2

¹All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort

²In the SDD, race information is not well populated and there are substantial proportions of "unknown" race and Hispanic indicator values. Specifically, two commercial Data Partners do not provide any race or ethnicity data.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1g. Aggregated Baseline Table, Sinuva Mometasone Furoate (MF) Single Use Incident on Self and No Cataracts Cohort in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021

Characteristic¹	Number	
Number of unique patients	297	
Demographics	Mean	Standard Deviation
Mean Age (Years)	49.9	12.6
Age (Years)	Number	Percent
0-1	0	0.0%
2-4	0	0.0%
5-9	0	0.0%
10-14	*****	*****
15-18	*****	*****
19-21	*****	*****
22-44	103	34.7%
45-64	132	44.4%
65-74	40	13.5%
75+	13	4.4%
Sex		
Female	122	41.1%
Male	175	58.9%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	0	0.0%
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	223	75.1%
White	66	22.2%
Hispanic Origin	*****	*****
Year		
2016	0	0.0%
2017	0	0.0%
2018	79	26.6%
2019	155	52.2%
2020	63	21.2%
Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters (AV)	12.5	8.8
Mean number of emergency room encounters (ED)	0.2	0.5
Mean number of inpatient hospital encounters (IP)	0.1	0.3
Mean number of non-acute institutional encounters (IS)	0.0	0.0
Mean number of other ambulatory encounters (OA)	1.6	3.0
Mean number of filled prescriptions	16.4	11.7
Mean number of generics	8.2	4.6
Mean number of unique drug classes	7.6	4.2

¹All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort

²In the SDD, race information is not well populated and there are substantial proportions of "unknown" race and Hispanic indicator values. Specifically, two commercial Data Partners do not provide any race or ethnicity data.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1h. Aggregated Baseline Table, Sinuva Mometasone Furoate (MF) Single Use Incident on Self and No Glaucoma Cohort in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021

Characteristic¹	Number	
Number of unique patients	384	
Demographics		
Mean Age (Years)	50.6	12.8
Age (Years)	Number	Percent
0-1	0	0.0%
2-4	0	0.0%
5-9	0	0.0%
10-14	*****	*****
15-18	*****	*****
19-21	*****	*****
22-44	130	33.9%
45-64	163	42.4%
65-74	58	15.1%
75+	21	5.5%
Sex		
Female	161	41.9%
Male	223	58.1%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	280	72.9%
White	93	24.2%
Hispanic Origin	*****	*****
Year		
2016	0	0.0%
2017	0	0.0%
2018	98	25.5%
2019	191	49.7%
2020	95	24.7%
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	12.9	9.1
Mean number of emergency room encounters (ED)	0.2	0.5
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.0
Mean number of other ambulatory encounters (OA)	1.6	2.8
Mean number of filled prescriptions	16.7	12.6
Mean number of generics	8.1	4.7
Mean number of unique drug classes	7.5	4.2

¹All metrics are based on total number of episodes per cohort, except for sex and race which are based on total number of unique patients; each baseline characteristic table represents one cohort

²In the SDD, race information is not well populated and there are substantial proportions of "unknown" race and Hispanic indicator values. Specifically, two commercial Data Partners do not provide any race or ethnicity data.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2a. Descriptive Statistics of Cumulative Mometasone Furoate (MF) Sinus Stent Exposure Episode Duration in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days, Overall

Exposures	Total Patients	Mean	Standard		Q1	Median	Q3	Maximum
			Deviation	Minimum				
Propel MF Sinus Stent Single Use Cohort	21,869	1.59	3.49	1	1	1	1	252
Sinuva MF Repeat Use Cohort	406	21.85	29.78	1	1	4	30	210
Sinuva MF Single Use Cohort	366	21.22	28.92	1	1	2	30	210
Sinuva MF Single Use and No Cataracts Cohort	270	22.77	28.51	1	1	30	30	180
Sinuva MF Single Use and No Glaucoma Cohort	349	21.37	29.27	1	1	2	30	210
Sinuva MF Single Use Incident on Self Cohort	403	21.71	29.67	1	1	2	30	210
Sinuva MF Single Use Incident on Self and No Cataracts Cohort	297	23.28	29.01	1	1	30	30	180
Sinuva MF Single Use Incident on Self and No Glaucoma Cohort	384	21.90	30.07	1	1	4	30	210

Table 2b. Descriptive Statistics of Cumulative Mometasone Furoate (MF) Sinus Stent Exposure Episode Duration in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days, by Sex

Exposures	Total Patients	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Propel MF Sinus Stent Single Use Cohort	21,869	1.59	3.49	1	1	1	1	252
Female	9,073	1.62	3.45	1	1	1	1	178
Male	12,796	1.56	3.53	1	1	1	1	252
Sinuva MF Repeat Use Cohort	406	21.85	29.78	1	1	4	30	210
Female	169	21.36	31.21	1	1	7	30	210
Male	237	22.20	28.78	1	1	2	30	180
Sinuva MF Single Use Cohort	366	21.22	28.92	1	1	2	30	210
Female	146	19.88	28.66	1	1	2	30	210
Male	220	22.11	29.12	1	1	2	30	180
Sinuva MF Single Use and No Cataracts Cohort	270	22.77	28.51	1	1	30	30	180
Female	108	20.30	24.99	1	1	30	30	180
Male	162	24.43	30.60	1	1	30	30	180
Sinuva MF Single Use and No Glaucoma Cohort	349	21.37	29.27	1	1	2	30	210
Female	142	20.00	28.95	1	1	2	30	210
Male	207	22.31	29.52	1	1	2	30	180
Sinuva MF Single Use Incident on Self Cohort	403	21.71	29.67	1	1	2	30	210
Female	167	20.90	30.93	1	1	6	30	210
Male	236	22.29	28.80	1	1	2	30	180
Sinuva MF Single Use Incident on Self and No Cataracts Cohort	297	23.28	29.01	1	1	30	30	180
Female	122	21.98	27.85	1	1	30	30	180
Male	175	24.18	29.84	1	1	30	30	180
Sinuva MF Single Use Incident on Self and No Glaucoma Cohort	384	21.90	30.07	1	1	4	30	210
Female	161	21.09	31.36	1	1	6	30	210
Male	223	22.48	29.16	1	1	2	30	180

Table 2c. Descriptive Statistics of Cumulative Mometasone Furoate (MF) Sinus Stent Exposure Episode Duration in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days, by Age Group (Years)

Exposures	Total Patients	Standard						
		Mean	Deviation	Minimum	Q1	Median	Q3	Maximum
Propel MF Sinus Stent Single Use Cohort	21,869	1.59	3.49	1	1	1	1	252
0-1	*****	1.60	0.89	1	1	1	2	3
2-4	*****	1.00	0.00	1	1	1	1	1
5-9	51	1.45	0.61	1	1	1	2	3
10-14	151	1.91	8.54	1	1	1	1	106
15-18	248	1.15	0.44	1	1	1	1	4
19-21	199	1.30	1.31	1	1	1	1	14
22-44	3,560	1.41	4.44	1	1	1	1	252
45-64	6,155	1.48	2.28	1	1	1	1	88
65-74	7,497	1.62	2.60	1	1	1	1	90
75+	3,997	1.87	5.05	1	1	1	2	178
Sinuva MF Repeat Use Cohort	406	21.85	29.78	1	1	4	30	210
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	1.00	-	1	1	1	1	1
15-18	*****	20.67	16.17	2	2	30	30	30
19-21	*****	15.63	22.21	1	1	1	30	60
22-44	131	25.15	31.95	1	1	30	30	210
45-64	174	25.01	27.54	1	1	30	30	180
65-74	67	12.52	31.02	1	1	1	1	180
75+	22	9.09	26.19	1	1	1	1	90
Sinuva MF Single Use Cohort	366	21.22	28.92	1	1	2	30	210
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	1.00	-	1	1	1	1	1
15-18	*****	16.00	19.80	2	2	16	30	30
19-21	*****	15.63	22.21	1	1	1	30	60
22-44	117	25.23	32.69	1	1	30	30	210
45-64	156	24.96	27.65	1	1	30	30	180
65-74	61	10.70	24.01	1	1	1	1	90
75+	21	5.24	19.42	1	1	1	1	90

Table 2c. Descriptive Statistics of Cumulative Mometasone Furoate (MF) Sinus Stent Exposure Episode Duration in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days, by Age Group (Years)

Exposures	Total Patients	Standard						
		Mean	Deviation	Minimum	Q1	Median	Q3	Maximum
Sinuva MF Single Use and No Cataracts Cohort	270	22.77	28.51	1	1	30	30	180
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	1.00	-	1	1	1	1	1
15-18	*****	16.00	19.80	2	2	16	30	30
19-21	*****	12.60	15.88	1	1	1	30	30
22-44	94	24.24	28.35	1	1	30	30	180
45-64	119	28.06	29.72	1	1	30	30	180
65-74	36	9.25	21.97	1	1	1	1	90
75+	13	7.85	24.68	1	1	1	1	90
Sinuva MF Single Use and No Glaucoma Cohort	349	21.37	29.27	1	1	2	30	210
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	1.00	-	1	1	1	1	1
15-18	*****	16.00	19.80	2	2	16	30	30
19-21	*****	15.63	22.21	1	1	1	30	60
22-44	117	25.23	32.69	1	1	30	30	210
45-64	148	24.68	27.94	1	1	30	30	180
65-74	52	11.27	25.51	1	1	1	1	90
75+	21	5.24	19.42	1	1	1	1	90
Sinuva MF Single Use Incident on Self Cohort	403	21.71	29.67	1	1	2	30	210
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	1.00	-	1	1	1	1	1
15-18	*****	20.67	16.17	2	2	30	30	30
19-21	*****	15.63	22.21	1	1	1	30	60
22-44	130	25.33	32.01	1	1	30	30	210
45-64	173	24.98	27.61	1	1	30	30	180
65-74	67	12.52	31.02	1	1	1	1	180
75+	21	5.24	19.42	1	1	1	1	90

Table 2c. Descriptive Statistics of Cumulative Mometasone Furoate (MF) Sinus Stent Exposure Episode Duration in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days, by Age Group (Years)

Exposures	Total Patients	Mean	Standard		Q1	Median	Q3	Maximum
			Deviation	Minimum				
Sinuva MF Single Use Incident on Self and No Cataracts Cohort	297	23.28	29.01	1	1	30	30	180
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	1.00	-	1	1	1	1	1
15-18	*****	20.67	16.17	2	2	30	30	30
19-21	*****	12.60	15.88	1	1	1	30	30
22-44	103	24.53	27.49	1	1	30	30	180
45-64	132	27.59	28.50	1	1	30	30	180
65-74	40	12.90	34.24	1	1	1	1	180
75+	13	7.85	24.68	1	1	1	1	90
Sinuva MF Single Use Incident on Self and No Glaucoma Cohort	384	21.90	30.07	1	1	4	30	210
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	1.00	-	1	1	1	1	1
15-18	*****	20.67	16.17	2	2	30	30	30
19-21	*****	15.63	22.21	1	1	1	30	60
22-44	130	25.33	32.01	1	1	30	30	210
45-64	163	24.83	27.99	1	1	30	30	180
65-74	58	13.31	32.96	1	1	1	1	180
75+	21	5.24	19.42	1	1	1	1	90

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3a. Descriptive Statistics of First Exposure to a Mometasone Furoate (MF) Sinus Stent in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, Episode Duration, in Days, Overall

Exposures	Total Episodes	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Propel MF Sinus Stent Single Use Cohort	21,869	1.02	0.46	1	1	1	1	34
Sinuva MF Repeat Use Cohort	406	18.73	22.98	1	1	4	30	180
Sinuva MF Single Use Cohort	366	17.92	21.26	1	1	1	30	90
Sinuva MF Single Use and No Cataracts Cohort	270	19.09	20.84	1	1	30	30	90
Sinuva MF Single Use and No Glaucoma Cohort	349	18.08	21.52	1	1	1	30	90
Sinuva MF Single Use Incident on Self Cohort	403	18.57	22.77	1	1	2	30	180
Sinuva MF Single Use Incident on Self and No Cataracts Cohort	297	19.82	22.30	1	1	30	30	180
Sinuva MF Single Use Incident on Self and No Glaucoma Cohort	384	18.75	23.09	1	1	4	30	180

Table 3b. Descriptive Statistics of First Exposure to a Mometasone Furoate (MF) Sinus Stent in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, Episode Duration, in Days, by Sex

Exposures	Total Episodes	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Propel MF Sinus Stent Single Use Cohort	21,869	1.02	0.46	1	1	1	1	34
Female	9,073	1.03	0.52	1	1	1	1	29
Male	12,796	1.02	0.42	1	1	1	1	34
Sinuva MF Repeat Use Cohort	406	18.73	22.98	1	1	4	30	180
Female	169	19.02	24.28	1	1	7	30	180
Male	237	18.52	22.06	1	1	1	30	90
Sinuva MF Single Use Cohort	366	17.92	21.26	1	1	1	30	90
Female	146	17.38	20.08	1	1	2	30	90
Male	220	18.28	22.04	1	1	1	30	90
Sinuva MF Single Use and No Cataracts Cohort	270	19.09	20.84	1	1	30	30	90
Female	108	18.31	19.23	1	1	30	30	90
Male	162	19.60	21.89	1	1	30	30	90
Sinuva MF Single Use and No Glaucoma Cohort	349	18.08	21.52	1	1	1	30	90
Female	142	17.43	20.21	1	1	2	30	90
Male	207	18.53	22.41	1	1	1	30	90
Sinuva MF Single Use Incident on Self Cohort	403	18.57	22.77	1	1	2	30	180
Female	167	18.53	23.78	1	1	6	30	180
Male	236	18.59	22.08	1	1	1	30	90
Sinuva MF Single Use Incident on Self and No Cataracts Cohort	297	19.82	22.30	1	1	30	30	180
Female	122	20.22	23.59	1	1	30	30	180
Male	175	19.54	21.41	1	1	30	30	90
Sinuva MF Single Use Incident on Self and No Glaucoma Cohort	384	18.75	23.09	1	1	4	30	180
Female	161	18.63	24.05	1	1	6	30	180
Male	223	18.84	22.42	1	1	1	30	90

Table 3c. Descriptive Statistics of First Exposure to a Mometasone Furoate (MF) Sinus Stent in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, Episode Duration, in Days, by Age Group (Years)

Exposures	Total Episodes	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Propel MF Sinus Stent Single Use Cohort	21,869	1.02	0.46	1	1	1	1	34
0-1	*****	1.00	0.00	1	1	1	1	1
2-4	*****	1.00	0.00	1	1	1	1	1
5-9	51	1.04	0.20	1	1	1	1	2
10-14	151	1.03	0.21	1	1	1	1	3
15-18	248	1.01	0.11	1	1	1	1	2
19-21	199	1.02	0.21	1	1	1	1	4
22-44	3,560	1.02	0.28	1	1	1	1	14
45-64	6,155	1.02	0.40	1	1	1	1	27
65-74	7,497	1.02	0.52	1	1	1	1	34
75+	3,997	1.04	0.59	1	1	1	1	28
Sinuva MF Repeat Use Cohort	406	18.73	22.98	1	1	4	30	180
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	1.00	-	1	1	1	1	1
15-18	*****	20.67	16.17	2	2	30	30	30
19-21	*****	11.88	15.01	1	1	1	30	30
22-44	131	21.01	22.21	1	1	30	30	90
45-64	174	21.18	19.27	1	1	30	30	90
65-74	67	12.04	30.54	1	1	1	1	180
75+	22	9.09	26.19	1	1	1	1	90
Sinuva MF Single Use Cohort	366	17.92	21.26	1	1	1	30	90
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	1.00	-	1	1	1	1	1
15-18	*****	16.00	19.80	2	2	16	30	30
19-21	*****	11.88	15.01	1	1	1	30	30
22-44	117	20.85	22.09	1	1	30	30	90
45-64	156	20.89	19.05	1	1	30	30	90
65-74	61	10.20	23.29	1	1	1	1	90
75+	21	5.24	19.42	1	1	1	1	90

Table 3c. Descriptive Statistics of First Exposure to a Mometasone Furoate (MF) Sinus Stent in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, Episode Duration, in Days, by Age Group (Years)

Exposures	Total Episodes	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Sinuva MF Single Use and No Cataracts Cohort	270	19.09	20.84	1	1	30	30	90
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	1.00	-	1	1	1	1	1
15-18	*****	16.00	19.80	2	2	16	30	30
19-21	*****	12.60	15.88	1	1	1	30	30
22-44	94	20.10	19.98	1	1	30	30	90
45-64	119	22.97	19.85	1	1	30	30	90
65-74	36	9.22	21.98	1	1	1	1	90
75+	13	7.85	24.68	1	1	1	1	90
Sinuva MF Single Use and No Glaucoma Cohort	349	18.08	21.52	1	1	1	30	90
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	1.00	-	1	1	1	1	1
15-18	*****	16.00	19.80	2	2	16	30	30
19-21	*****	11.88	15.01	1	1	1	30	30
22-44	117	20.85	22.09	1	1	30	30	90
45-64	148	20.79	19.34	1	1	30	30	90
65-74	52	10.67	24.72	1	1	1	1	90
75+	21	5.24	19.42	1	1	1	1	90
Sinuva MF Single Use Incident on Self Cohort	403	18.57	22.77	1	1	2	30	180
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	1.00	-	1	1	1	1	1
15-18	*****	20.67	16.17	2	2	30	30	30
19-21	*****	11.88	15.01	1	1	1	30	30
22-44	130	21.16	22.23	1	1	30	30	90
45-64	173	21.13	19.32	1	1	30	30	90
65-74	67	12.04	30.54	1	1	1	1	180
75+	21	5.24	19.42	1	1	1	1	90

Table 3c. Descriptive Statistics of First Exposure to a Mometasone Furoate (MF) Sinus Stent in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, Episode Duration, in Days, by Age Group (Years)

Exposures	Total Episodes	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Sinuva MF Single Use Incident on Self and No Cataracts Cohort	297	19.82	22.30	1	1	30	30	180
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	1.00	-	1	1	1	1	1
15-18	*****	20.67	16.17	2	2	30	30	30
19-21	*****	12.60	15.88	1	1	1	30	30
22-44	103	20.46	19.39	1	1	30	30	90
45-64	132	23.01	19.22	1	1	30	30	90
65-74	40	12.88	34.25	1	1	1	1	180
75+	13	7.85	24.68	1	1	1	1	90
Sinuva MF Single Use Incident on Self and No Glaucoma Cohort	384	18.75	23.09	1	1	4	30	180
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	1.00	-	1	1	1	1	1
15-18	*****	20.67	16.17	2	2	30	30	30
19-21	*****	11.88	15.01	1	1	1	30	30
22-44	130	21.16	22.23	1	1	30	30	90
45-64	163	21.12	19.63	1	1	30	30	90
65-74	58	12.76	32.46	1	1	1	1	180
75+	21	5.24	19.42	1	1	1	1	90

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 4a. Descriptive Statistics of All Exposure Episode Durations to Mometasone Furoate (MF) Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days, Overall

Exposures	Total Episodes	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Propel MF Sinus Stent Single Use Cohort	33,207	1.04	0.99	1	1	1	1	112
Sinuva MF Repeat Use Cohort	453	19.58	22.62	1	1	30	30	180
Sinuva MF Single Use Cohort	410	18.94	21.10	1	1	30	30	120
Sinuva MF Single Use and No Cataracts Cohort	305	20.16	20.82	1	1	30	30	120
Sinuva MF Single Use and No Glaucoma Cohort	391	19.07	21.36	1	1	30	30	120
Sinuva MF Single Use Incident on Self Cohort	450	19.45	22.42	1	1	30	30	180
Sinuva MF Single Use Incident on Self and No Cataracts Cohort	333	20.76	22.07	1	1	30	30	180
Sinuva MF Single Use Incident on Self and No Glaucoma Cohort	429	19.60	22.73	1	1	30	30	180

Table 4b. Descriptive Statistics of All Exposure Episode Durations to Mometasone Furoate (MF) Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days, by Sex

Exposures	Total Episodes	Mean	Standard					
			Deviation	Minimum	Q1	Median	Q3	Maximum
Propel MF Sinus Stent Single Use Cohort	33,207	1.04	0.99	1	1	1	1	112
Female	14,135	1.04	0.52	1	1	1	1	29
Male	19,072	1.05	1.23	1	1	1	1	112
Sinuva MF Repeat Use Cohort	453	19.58	22.62	1	1	30	30	180
Female	187	19.30	23.44	1	1	30	30	180
Male	266	19.78	22.06	1	1	30	30	120
Sinuva MF Single Use Cohort	410	18.94	21.10	1	1	30	30	120
Female	162	17.91	19.52	1	1	28	30	90
Male	248	19.62	22.09	1	1	30	30	120
Sinuva MF Single Use and No Cataracts Cohort	305	20.16	20.82	1	1	30	30	120
Female	118	18.58	18.80	1	1	30	30	90
Male	187	21.16	21.98	1	1	30	30	120
Sinuva MF Single Use and No Glaucoma Cohort	391	19.07	21.36	1	1	30	30	120
Female	158	17.97	19.63	1	1	28	30	90
Male	233	19.82	22.48	1	1	30	30	120
Sinuva MF Single Use Incident on Self Cohort	450	19.45	22.42	1	1	30	30	180
Female	185	18.86	22.97	1	1	28	30	180
Male	265	19.85	22.07	1	1	30	30	120
Sinuva MF Single Use Incident on Self and No Cataracts Cohort	333	20.76	22.07	1	1	30	30	180
Female	132	20.31	22.96	1	1	30	30	180
Male	201	21.05	21.52	1	1	30	30	120
Sinuva MF Single Use Incident on Self and No Glaucoma Cohort	429	19.60	22.73	1	1	30	30	180
Female	179	18.97	23.19	1	1	28	30	180
Male	250	20.06	22.43	1	1	30	30	120

Table 4c. Descriptive Statistics of All Exposure Episode Durations to Mometasone Furoate (MF) Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days, by Age Group (Years)

Exposures	Total Episodes	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Propel MF Sinus Stent Single Use Cohort	33,207	1.04	0.99	1	1	1	1	112
0-1	*****	*****	*****	*****	*****	*****	*****	*****
2-4	*****	*****	*****	*****	*****	*****	*****	*****
5-9	72	1.03	0.17	1	1	1	1	2
10-14	180	1.60	4.43	1	1	1	1	45
15-18	281	1.01	0.10	1	1	1	1	2
19-21	244	1.06	0.62	1	1	1	1	10
22-44	4,640	1.08	2.20	1	1	1	1	112
45-64	8,869	1.03	0.36	1	1	1	1	27
65-74	11,786	1.03	0.51	1	1	1	1	34
75+	7,121	1.05	0.54	1	1	1	1	28
Sinuva MF Repeat Use Cohort	453	19.58	22.62	1	1	30	30	180
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	*****	-	*****	*****	*****	*****	*****
15-18	*****	20.67	16.17	2	2	30	30	30
19-21	*****	13.89	15.28	1	1	1	30	30
22-44	148	22.26	22.69	1	1	30	30	120
45-64	200	21.76	18.42	1	1	30	30	90
65-74	70	11.99	30.01	1	1	1	1	180
75+	22	9.09	26.19	1	1	1	1	90
Sinuva MF Single Use Cohort	410	18.94	21.10	1	1	30	30	120
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	*****	-	*****	*****	*****	*****	*****
15-18	*****	16.00	19.80	2	2	16	30	30
19-21	*****	13.89	15.28	1	1	1	30	30
22-44	133	22.20	22.71	1	1	30	30	120
45-64	181	21.51	18.18	1	1	30	30	90
65-74	63	10.37	23.08	1	1	1	1	90
75+	21	5.24	19.42	1	1	1	1	90

Table 4c. Descriptive Statistics of All Exposure Episode Durations to Mometasone Furoate Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days, by Age Group (Years)

Exposures	Total Episodes	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Sinuva MF Single Use and No Cataracts Cohort	305	20.16	20.82	1	1	30	30	120
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	*****	-	*****	*****	*****	*****	*****
15-18	*****	16.00	19.80	2	2	16	30	30
19-21	*****	12.60	15.88	1	1	1	30	30
22-44	104	21.91	21.51	1	1	30	30	120
45-64	143	23.35	18.64	1	1	30	30	90
65-74	37	9.00	21.71	1	1	1	1	90
75+	13	7.85	24.68	1	1	1	1	90
Sinuva MF Single Use and No Glaucoma Cohort	391	19.07	21.36	1	1	30	30	120
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	*****	-	*****	*****	*****	*****	*****
15-18	*****	16.00	19.80	2	2	16	30	30
19-21	*****	13.89	15.28	1	1	1	30	30
22-44	133	22.20	22.71	1	1	30	30	120
45-64	171	21.36	18.48	1	1	30	30	90
65-74	54	10.85	24.43	1	1	1	1	90
75+	21	5.24	19.42	1	1	1	1	90
Sinuva MF Single Use Incident on Self Cohort	450	19.45	22.42	1	1	30	30	180
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	*****	-	*****	*****	*****	*****	*****
15-18	*****	20.67	16.17	2	2	30	30	30
19-21	*****	13.89	15.28	1	1	1	30	30
22-44	147	22.40	22.70	1	1	30	30	120
45-64	199	21.71	18.45	1	1	30	30	90
65-74	70	11.99	30.01	1	1	1	1	180
75+	21	5.24	19.42	1	1	1	1	90

Table 4c. Descriptive Statistics of All Exposure Episode Durations to Mometasone Furoate Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days, by Age Group (Years)

Exposures	Total Episodes	Mean	Standard		Q1	Median	Q3	Maximum
			Deviation	Minimum				
Sinuva MF Single Use Incident on Self and No Cataracts Cohort	333	20.76	22.07	1	1	30	30	180
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	*****	-	*****	*****	*****	*****	*****
15-18	*****	20.67	16.17	2	2	30	30	30
19-21	*****	12.60	15.88	1	1	1	30	30
22-44	114	22.17	20.79	1	1	30	30	120
45-64	156	23.35	18.19	1	1	30	30	90
65-74	41	12.59	33.87	1	1	1	1	180
75+	13	7.85	24.68	1	1	1	1	90
Sinuva MF Single Use Incident on Self and No Glaucoma Cohort	429	19.60	22.73	1	1	30	30	180
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	*****	-	*****	*****	*****	*****	*****
15-18	*****	20.67	16.17	2	2	30	30	30
19-21	*****	13.89	15.28	1	1	1	30	30
22-44	147	22.40	22.70	1	1	30	30	120
45-64	187	21.64	18.77	1	1	30	30	90
65-74	61	12.66	31.79	1	1	1	1	180
75+	21	5.24	19.42	1	1	1	1	90

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 5a. Descriptive Statistics of Days Supplied per Dispensing for Mometasone Furoate (MF) Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, Overall

Exposures	Total Dispensing's	Mean	Standard		Q1	Median	Q3	Maximum
			Deviation	Minimum				
Propel MF Sinus Stent Single Use Cohort	34,674	1.00	0.00	1	1	1	1	1
Sinuva MF Repeat Use Cohort	461	19.25	21.22	1	1	30	30	90
Sinuva MF Single Use Cohort	416	18.67	20.44	1	1	30	30	90
Sinuva MF Single Use and No Cataracts Cohort	311	19.77	19.94	1	1	30	30	90
Sinuva MF Single Use and No Glaucoma Cohort	397	18.79	20.68	1	1	30	30	90
Sinuva MF Single Use Incident on Self Cohort	458	19.11	21.01	1	1	30	30	90
Sinuva MF Single Use Incident on Self and No Cataracts Cohort	340	20.34	20.15	1	1	30	30	90
Sinuva MF Single Use Incident on Self and No Glaucoma Cohort	436	19.29	21.27	1	1	30	30	90

Table 5b. Descriptive Statistics of Days Supplied per Dispensing for Mometasone Furoate (MF) Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, by Sex

Exposures	Total Dispensings	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Propel MF Sinus Stent Single Use Cohort	34,674	1.00	0.00	1	1	1	1	1
Female	14,653	1.00	0.00	1	1	1	1	1
Male	20,021	1.00	0.00	1	1	1	1	1
Sinuva MF Repeat Use Cohort	461	19.25	21.22	1	1	30	30	90
Female	191	18.90	21.23	1	1	30	30	90
Male	270	19.49	21.25	1	1	30	30	90
Sinuva MF Single Use Cohort	416	18.67	20.44	1	1	30	30	90
Female	164	17.70	19.21	1	1	28	30	90
Male	252	19.31	21.22	1	1	30	30	90
Sinuva MF Single Use and No Cataracts Cohort	311	19.77	19.94	1	1	30	30	90
Female	120	18.27	18.39	1	1	30	30	90
Male	191	20.72	20.85	1	1	30	30	90
Sinuva MF Single Use and No Glaucoma Cohort	397	18.79	20.68	1	1	30	30	90
Female	160	17.75	19.31	1	1	28	30	90
Male	237	19.49	21.56	1	1	30	30	90
Sinuva MF Single Use Incident on Self Cohort	458	19.11	21.01	1	1	30	30	90
Female	189	18.47	20.69	1	1	28	30	90
Male	269	19.56	21.26	1	1	30	30	90
Sinuva MF Single Use Incident on Self and No Cataracts Cohort	340	20.34	20.15	1	1	30	30	90
Female	135	19.86	19.75	1	1	30	30	90
Male	205	20.65	20.45	1	1	30	30	90
Sinuva MF Single Use Incident on Self and No Glaucoma Cohort	436	19.29	21.27	1	1	30	30	90
Female	182	18.66	20.87	1	1	29	30	90
Male	254	19.74	21.58	1	1	30	30	90

Table 5c. Descriptive Statistics of Days Supplied per Dispensing for Mometasone Furoate (MF) Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, by Age Group (Years)

Exposures	Total Dispensings	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Propel MF Sinus Stent Single Use Cohort	34,674	1.00	0.00	1	1	1	1	1
0-1	*****	1.00	0.00	1	1	1	1	1
2-4	*****	1.00	0.00	1	1	1	1	1
5-9	74	1.00	0.00	1	1	1	1	1
10-14	288	1.00	0.00	1	1	1	1	1
15-18	284	1.00	0.00	1	1	1	1	1
19-21	259	1.00	0.00	1	1	1	1	1
22-44	5,010	1.00	0.00	1	1	1	1	1
45-64	9,119	1.00	0.00	1	1	1	1	1
65-74	12,147	1.00	0.00	1	1	1	1	1
75+	7,479	1.00	0.00	1	1	1	1	1
Sinuva MF Repeat Use Cohort	461	19.25	21.22	1	1	30	30	90
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	1.00	-	1	1	1	1	1
15-18	*****	15.50	16.74	1	1	16	30	30
19-21	*****	13.89	15.28	1	1	1	30	30
22-44	152	21.68	21.31	1	1	30	30	90
45-64	202	21.54	18.21	1	1	30	30	90
65-74	71	11.82	25.66	1	1	1	1	90
75+	22	9.09	26.19	1	1	1	1	90
Sinuva MF Single Use Cohort	416	18.67	20.44	1	1	30	30	90
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	1.00	-	1	1	1	1	1
15-18	*****	10.67	16.74	1	1	1	30	30
19-21	*****	13.89	15.28	1	1	1	30	30
22-44	137	21.55	21.17	1	1	30	30	90
45-64	182	21.40	17.92	1	1	30	30	90
65-74	63	10.37	23.08	1	1	1	1	90
75+	21	5.24	19.42	1	1	1	1	90

Table 5c. Descriptive Statistics of Days Supplied per Dispensing for Mometasone Furoate (MF) Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, by Age Group (Years)

Exposures	Total Dispensings	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Sinuva MF Single Use and No Cataracts Cohort	311	19.77	19.94	1	1	30	30	90
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	1.00	-	1	1	1	1	1
15-18	*****	10.67	16.74	1	1	1	30	30
19-21	*****	12.60	15.88	1	1	1	30	30
22-44	108	21.11	19.45	1	1	30	30	90
45-64	144	23.19	18.33	1	1	30	30	90
65-74	37	9.00	21.71	1	1	1	1	90
75+	13	7.85	24.68	1	1	1	1	90
Sinuva MF Single Use and No Glaucoma Cohort	397	18.79	20.68	1	1	30	30	90
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	1.00	-	1	1	1	1	1
15-18	*****	10.67	16.74	1	1	1	30	30
19-21	*****	13.89	15.28	1	1	1	30	30
22-44	137	21.55	21.17	1	1	30	30	90
45-64	172	21.23	18.21	1	1	30	30	90
65-74	54	10.85	24.43	1	1	1	1	90
75+	21	5.24	19.42	1	1	1	1	90
Sinuva MF Single Use Incident on Self Cohort	458	19.11	21.01	1	1	30	30	90
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	1.00	-	1	1	1	1	1
15-18	*****	15.50	16.74	1	1	16	30	30
19-21	*****	13.89	15.28	1	1	1	30	30
22-44	151	21.81	21.31	1	1	30	30	90
45-64	201	21.50	18.24	1	1	30	30	90
65-74	71	11.82	25.66	1	1	1	1	90
75+	21	5.24	19.42	1	1	1	1	90

Table 5c. Descriptive Statistics of Days Supplied per Dispensing for Mometasone Furoate (MF) Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, by Age Group (Years)

Exposures	Total Dispensings	Standard			Q1	Median	Q3	Maximum
		Mean	Deviation	Minimum				
Sinuva MF Single Use Incident on Self and No Cataracts Cohort	340	20.34	20.15	1	1	30	30	90
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	1.00	-	1	1	1	1	1
15-18	*****	15.50	16.74	1	1	16	30	30
19-21	*****	12.60	15.88	1	1	1	30	30
22-44	118	21.42	18.88	1	1	30	30	90
45-64	157	23.20	17.91	1	1	30	30	90
65-74	42	12.29	26.98	1	1	1	1	90
75+	13	7.85	24.68	1	1	1	1	90
Sinuva MF Single Use Incident on Self and No Glaucoma Cohort	436	19.29	21.27	1	1	30	30	90
0-1	0	-	-	-	-	-	-	-
2-4	0	-	-	-	-	-	-	-
5-9	0	-	-	-	-	-	-	-
10-14	*****	1.00	-	1	1	1	1	1
15-18	*****	15.50	16.74	1	1	16	30	30
19-21	*****	13.89	15.28	1	1	1	30	30
22-44	151	21.81	21.31	1	1	30	30	90
45-64	188	21.53	18.53	1	1	30	30	90
65-74	62	12.45	27.03	1	1	1	1	90
75+	21	5.24	19.42	1	1	1	1	90

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 6a. Descriptive Statistics of the Length of All Gaps between Treatment Episodes for Mometasone Furoate (MF) Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days

Exposures	Total Gaps	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Propel MF Sinus Stent Single Use Cohort	11,338	140.10	223.11	1	13	36	167	1,518
Sinuva MF Repeat Use Cohort	47	118.68	68.79	6	72	96	167	278
Sinuva MF Single Use Cohort	44	116.89	66.27	6	69	101	164	264
Sinuva MF Single Use and No Cataracts Cohort	35	124.40	60.86	33	78	108	173	264
Sinuva MF Single Use and No Glaucoma Cohort	42	118.38	67.35	6	73	102	167	264
Sinuva MF Single Use Incident on Self Cohort	47	118.68	68.79	6	72	96	167	278
Sinuva MF Single Use Incident on Self and No Cataracts Cohort	36	123.31	60.34	33	80	107	170	264
Sinuva MF Single Use Incident on Self and No Glaucoma Cohort	45	120.16	69.83	6	73	96	167	278

Table 6b: Descriptive Statistics of the Length of All Gaps between Treatment Episodes for Mometasone Furoate (MF) Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days, by Sex

Exposures	Total Gaps	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Propel MF Sinus Stent Single Use Cohort	11,338	140.10	223.11	1	13	36	167	1,518
Female	5,062	139.31	220.66	1	12	39	165	1,475
Male	6,276	140.75	225.08	1	13	35	168	1,518
Sinuva MF Repeat Use Cohort	47	118.68	68.79	6	72	96	167	278
Female	18	127.89	89.07	6	51	84	208	278
Male	29	112.97	53.57	28	81	106	143	264
Sinuva MF Single Use Cohort	44	116.89	66.27	6	69	101	164	264
Female	16	122.00	85.11	6	50	84	197	264
Male	28	113.96	54.27	28	77	107	148	264
Sinuva MF Single Use and No Cataracts Cohort	35	124.40	60.86	33	78	108	173	264
Female	10	146.90	73.76	36	78	170	208	242
Male	25	115.40	53.96	33	81	106	143	264
Sinuva MF Single Use and No Glaucoma Cohort	42	118.38	67.35	6	73	102	167	264
Female	16	122.00	85.11	6	50	84	197	264
Male	26	116.15	55.48	28	81	109	152	264
Sinuva MF Single Use Incident on Self Cohort	47	118.68	68.79	6	72	96	167	278
Female	18	127.89	89.07	6	51	84	208	278
Male	29	112.97	53.57	28	81	106	143	264
Sinuva MF Single Use Incident on Self and No Cataracts Cohort	36	123.31	60.34	33	80	107	170	264
Female	10	146.90	73.76	36	78	170	208	242
Male	26	114.23	53.20	33	81	101	143	264
Sinuva MF Single Use Incident on Self and No Glaucoma Cohort	45	120.16	69.83	6	73	96	167	278
Female	18	127.89	89.07	6	51	84	208	278
Male	27	115.00	54.73	28	81	108	152	264

Table 6c. Descriptive Statistics of the Length of All Gaps between Treatment Episodes for Mometasone Furoate (MF) Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days, by Age Group (Years)

Exposures	Total Gaps	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Propel MF Sinus Stent Single Use Cohort	11,338	140.10	223.11	1	13	36	167	1,518
00-01	*****	358.00	581.20	12	12	33	1,029	1,029
02-04	0	-	-	-	-	-	-	-
05-09	*****	219.33	212.63	1	27	158	349	622
10-14	29	238.97	229.23	8	55	222	389	868
15-18	33	281.33	309.80	1	27	164	381	1,166
19-21	45	232.62	286.04	1	27	128	351	1,406
22-44	1,080	170.19	235.93	1	14	68	223	1,210
45-64	2,714	157.91	235.28	1	13	49	202	1,454
65-74	4,289	140.51	224.12	1	13	35	159	1,475
75+	3,124	109.20	198.12	1	6	27	111	1,518
Sinuva MF Repeat Use Cohort	47	118.68	68.79	6	72	96	167	278
00-01	0	-	-	-	-	-	-	-
02-04	0	-	-	-	-	-	-	-
05-09	0	-	-	-	-	-	-	-
10-14	0	-	-	-	-	-	-	-
15-18	0	-	-	-	-	-	-	-
19-21	*****	117.00	-	117	117	117	117	117
22-44	*****	88.06	61.83	6	43	78	96	208
45-64	26	133.69	66.43	36	81	112	173	278
65-74	*****	162.67	96.44	72	72	152	264	264
75+	0	-	-	-	-	-	-	-
Sinuva MF Single Use Cohort	44	116.89	66.27	6	69	101	164	264
00-01	0	-	-	-	-	-	-	-
02-04	0	-	-	-	-	-	-	-
05-09	0	-	-	-	-	-	-	-
10-14	0	-	-	-	-	-	-	-
15-18	0	-	-	-	-	-	-	-
19-21	*****	117.00	-	117	117	117	117	117
22-44	16	88.25	63.85	6	39	76	118	208
45-64	25	127.92	60.78	36	81	109	167	264
65-74	*****	208.00	79.20	152	152	208	264	264
75+	0	-	-	-	-	-	-	-

Table 6c. Descriptive Statistics of the Length of All Gaps between Treatment Episodes for Mometasone Furoate Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days, by Age Group (Years)

Exposures	Total Gaps	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Sinuva MF Single Use and No Cataracts Cohort	35	124.40	60.86	33	78	108	173	264
00-01	0	-	-	-	-	-	-	-
02-04	0	-	-	-	-	-	-	-
05-09	0	-	-	-	-	-	-	-
10-14	0	-	-	-	-	-	-	-
15-18	0	-	-	-	-	-	-	-
19-21	0	-	-	-	-	-	-	-
22-44	*****	116.50	64.05	33	73	96	185	208
45-64	24	126.54	61.69	36	80	109	170	264
65-74	*****	152.00	-	152	152	152	152	152
75+	0	-	-	-	-	-	-	-
Sinuva MF Single Use and No Glaucoma Cohort	42	118.38	67.35	6	73	102	167	264
00-01	0	-	-	-	-	-	-	-
02-04	0	-	-	-	-	-	-	-
05-09	0	-	-	-	-	-	-	-
10-14	0	-	-	-	-	-	-	-
15-18	0	-	-	-	-	-	-	-
19-21	*****	117.00	-	117	117	117	117	117
22-44	*****	88.25	63.85	6	39	76	118	208
45-64	23	131.61	61.76	36	81	115	173	264
65-74	*****	208.00	79.20	152	152	208	264	264
75+	0	-	-	-	-	-	-	-
Sinuva MF Single Use Incident on Self Cohort	47	118.68	68.79	6	72	96	167	278
00-01	0	-	-	-	-	-	-	-
02-04	0	-	-	-	-	-	-	-
05-09	0	-	-	-	-	-	-	-
10-14	0	-	-	-	-	-	-	-
15-18	0	-	-	-	-	-	-	-
19-21	*****	117.00	-	117	117	117	117	117
22-44	*****	88.06	61.83	6	43	78	96	208
45-64	26	133.69	66.43	36	81	112	173	278
65-74	*****	162.67	96.44	72	72	152	264	264
75+	0	-	-	-	-	-	-	-

Table 6c. Descriptive Statistics of the Length of All Gaps between Treatment Episodes for Mometasone Furoate Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021, in Days, by Age Group (Years)

Exposures	Total Gaps	Mean	Standard	Minimum	Q1	Median	Q3	Maximum
			Deviation					
Sinuva MF Single Use Incident on Self and No Cataracts Cohort	36	123.31	60.34	33	80	107	170	264
00-01	0	-	-	-	-	-	-	-
02-04	0	-	-	-	-	-	-	-
05-09	0	-	-	-	-	-	-	-
10-14	0	-	-	-	-	-	-	-
15-18	0	-	-	-	-	-	-	-
19-21	0	-	-	-	-	-	-	-
22-44	*****	113.64	61.50	33	73	96	185	208
45-64	24	126.54	61.69	36	80	109	170	264
65-74	*****	152.00	-	152	152	152	152	152
75+	0	-	-	-	-	-	-	-
Sinuva MF Single Use Incident on Self and No Glaucoma Cohort	45	120.16	69.83	6	73	96	167	278
00-01	0	-	-	-	-	-	-	-
02-04	0	-	-	-	-	-	-	-
05-09	0	-	-	-	-	-	-	-
10-14	0	-	-	-	-	-	-	-
15-18	0	-	-	-	-	-	-	-
19-21	*****	117.00	-	117	117	117	117	117
22-44	*****	88.06	61.83	6	43	78	96	208
45-64	24	137.71	67.39	36	83	122	180	278
65-74	*****	162.67	96.44	72	72	152	264	264
75+	0	-	-	-	-	-	-	-

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 7. Counts of Reason for Censoring, All Episodes and First Episode of Mometasone Furoate (MF) Sinus Stents in the Sentinel Distributed Database (SDD) between January 1, 2016 and April 30, 2021

	Total		Disenrollment		Evidence of death		Data Partner/Query end date		Episode end	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Exposures										
Propel MF Sinus Stent Single Use Cohort	33,207	100.0	15	0.0	25	0.1	14	0.0	33,206	100.0
Sinuva MF Repeat Use Cohort	453	100.0	*****	0.7	0	0.0	*****	0.7	450	99.3
Sinuva MF Single Use Cohort	410	100.0	*****	0.7	0	0.0	*****	0.5	408	99.5
Sinuva MF Single Use and No Cataracts Cohort	305	100.0	*****	1.0	0	0.0	*****	0.3	304	99.7
Sinuva MF Single Use and No Glaucoma Cohort	391	100.0	*****	0.8	0	0.0	*****	0.5	389	99.5
Sinuva MF Single Use Incident on Self Cohort	450	100.0	*****	0.7	0	0.0	*****	0.7	447	99.3
Sinuva MF Single Use Incident on Self and No Cataracts Cohort	333	100.0	*****	0.9	0	0.0	*****	0.6	331	99.4
Sinuva MF Single Use Incident on Self and No Glaucoma Cohort	429	100.0	*****	0.7	0	0.0	*****	0.7	426	99.3
Patients' First Episode										
Propel MF Sinus Stent Single Use Cohort	21,869	100.0	*****	0.0	20	0.1	*****	0.0	21,868	100.0
Sinuva MF Repeat Use Cohort	406	100.0	*****	0.7	0	0.0	*****	0.7	403	99.3
Sinuva MF Single Use Cohort	366	100.0	*****	0.8	0	0.0	*****	0.5	364	99.5
Sinuva MF Single Use and No Cataracts Cohort	270	100.0	*****	1.1	0	0.0	*****	0.4	269	99.6
Sinuva MF Single Use and No Glaucoma Cohort	349	100.0	*****	0.9	0	0.0	*****	0.6	347	99.4
Sinuva MF Single Use Incident on Self Cohort	403	100.0	*****	0.7	0	0.0	*****	0.7	400	99.3
Sinuva MF Single Use Incident on Self and No Cataracts Cohort	297	100.0	*****	1.0	0	0.0	*****	0.7	295	99.3
Sinuva MF Single Use Incident on Self and No Glaucoma Cohort	384	100.0	*****	0.8	0	0.0	*****	0.8	381	99.2

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Query Distribution Date

Masked ID	DP Start Date	DP End Date ¹
DP01	01/01/2000	02/28/2019
DP02	01/01/2000	02/28/2021
DP03	01/01/2000	02/28/2021
DP04	01/01/2006	08/31/2020
DP05	01/01/2007	10/31/2020
DP06	01/01/2000	04/30/2021
DP07	01/01/2000	06/30/2020
DP08	01/01/2005	10/31/2020
DP09	01/01/2000	12/31/2018
DP10	01/01/2008	08/31/2020
DP11	01/01/2000	07/31/2019
DP12	01/01/2004	08/31/2019
DP13	01/01/2008	12/31/2020
DP14	01/01/2010	09/30/2020

¹ End Date represents the earliest of: (1) query end date, or (2) most recent year-month of data for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month. The start and end dates are based on the minimum and maximum dates within each DP. The month with the maximum date must have at least 80% of the number of records in the previous month

Appendix B. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), and Healthcare Common Procedure Coding System, Level II (HCPCS) Procedure Codes Used to Define Exposures in this Request

Code	Description	Code	
		Category	Code Type
Propel			
0406T	Nasal endoscopy, surgical, ethmoid sinus, placement of drug eluting implant	Procedure	CPT-3
0407T	Nasal endoscopy, surgical, ethmoid sinus, placement of drug eluting implant; with polypectomy, biopsy or debridement	Procedure	CPT-3
31299	Unlisted procedure, accessory sinuses	Procedure	CPT-4
C2625	Stent, noncoronary, temporary, with delivery system	Procedure	HCPCS
J3490	Unclassified drugs	Procedure	HCPCS
S1090	Mometasone furoate sinus implant, 370 micrograms	Procedure	HCPCS
Sinuva			
C9122	Mometasone furoate sinus implant, 10 micrograms (Sinuva)	Procedure	HCPCS
J7401	Mometasone furoate sinus implant, 10 mcg	Procedure	HCPCS
J7402	Mometasone furoate sinus implant, (Sinuva), 10 micrograms.	Procedure	HCPCS

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request

Generic Name	Brand Name
	Propel
mometasone furoate 0.37 MG	Propel
	Sinuva
mometasone furoate	Sinuva

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Category	Code Type
Nasal Polyp			
471.0	Polyp of nasal cavity	Diagnosis	ICD-9-CM
471.1	Polypoid sinus degeneration	Diagnosis	ICD-9-CM
471.8	Other polyp of sinus	Diagnosis	ICD-9-CM
471.9	Unspecified nasal polyp	Diagnosis	ICD-9-CM
J33	Nasal polyp	Diagnosis	ICD-10-CM
J33.0	Polyp of nasal cavity	Diagnosis	ICD-10-CM
J33.1	Polypoid sinus degeneration	Diagnosis	ICD-10-CM
J33.8	Other polyp of sinus	Diagnosis	ICD-10-CM
J33.9	Nasal polyp, unspecified	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
Propel			
0406T	Nasal endoscopy, surgical, ethmoid sinus, placement of drug eluting implant	Procedure	CPT-3
0407T	Nasal endoscopy, surgical, ethmoid sinus, placement of drug eluting implant; with	Procedure	CPT-3
31299	Unlisted procedure, accessory sinuses	Procedure	CPT-4
C2625	Stent, noncoronary, temporary, with delivery system	Procedure	HCPCS
J3490	Unclassified drugs	Procedure	HCPCS
S1090	Mometasone furoate sinus implant, 370 micrograms	Procedure	HCPCS
Sinuva			
C9122	Mometasone furoate sinus implant, 10 micrograms (Sinuva)	Procedure	HCPCS
J7401	Mometasone furoate sinus implant, 10 mcg	Procedure	HCPCS
J7402	Mometasone furoate sinus implant, (Sinuva), 10 micrograms.	Procedure	HCPCS
Glaucoma			
365	Glaucoma	Diagnosis	ICD-9-CM
365.0	Borderline glaucoma (glaucoma suspect)	Diagnosis	ICD-9-CM
365.00	Unspecified preglaucoma	Diagnosis	ICD-9-CM
365.01	Borderline glaucoma, open angle with borderline findings, low risk	Diagnosis	ICD-9-CM
365.02	Borderline glaucoma with anatomical narrow angle	Diagnosis	ICD-9-CM
365.03	Borderline glaucoma with steroid responders	Diagnosis	ICD-9-CM
365.04	Borderline glaucoma with ocular hypertension	Diagnosis	ICD-9-CM
365.05	Open angle with borderline findings, high risk	Diagnosis	ICD-9-CM
365.06	Primary angle closure without glaucoma damage	Diagnosis	ICD-9-CM
365.1	Open-angle glaucoma	Diagnosis	ICD-9-CM
365.10	Unspecified open-angle glaucoma	Diagnosis	ICD-9-CM
365.11	Primary open-angle glaucoma	Diagnosis	ICD-9-CM
365.12	Low tension open-angle glaucoma	Diagnosis	ICD-9-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
365.13	Pigmentary open-angle glaucoma	Diagnosis	ICD-9-CM
365.14	Open-angle glaucoma of childhood	Diagnosis	ICD-9-CM
365.15	Residual stage of open angle glaucoma	Diagnosis	ICD-9-CM
365.2	Primary angle-closure glaucoma	Diagnosis	ICD-9-CM
365.20	Unspecified primary angle-closure glaucoma	Diagnosis	ICD-9-CM
365.21	Intermittent angle-closure glaucoma	Diagnosis	ICD-9-CM
365.22	Acute angle-closure glaucoma	Diagnosis	ICD-9-CM
365.23	Chronic angle-closure glaucoma	Diagnosis	ICD-9-CM
365.24	Residual stage of angle-closure glaucoma	Diagnosis	ICD-9-CM
365.3	Corticosteroid-induced glaucoma	Diagnosis	ICD-9-CM
365.31	Corticosteroid-induced glaucoma, glaucomatous stage	Diagnosis	ICD-9-CM
365.32	Corticosteroid-induced glaucoma, residual stage	Diagnosis	ICD-9-CM
365.4	Glaucoma associated with congenital anomalies, dystrophies, and systemic syndromes	Diagnosis	ICD-9-CM
365.41	Glaucoma associated with chamber angle anomalies	Diagnosis	ICD-9-CM
365.42	Glaucoma associated with anomalies of iris	Diagnosis	ICD-9-CM
365.43	Glaucoma associated with other anterior segment anomalies	Diagnosis	ICD-9-CM
365.44	Glaucoma associated with systemic syndromes	Diagnosis	ICD-9-CM
365.5	Glaucoma associated with disorders of the lens	Diagnosis	ICD-9-CM
365.51	Phacolytic glaucoma	Diagnosis	ICD-9-CM
365.52	Pseudoexfoliation glaucoma	Diagnosis	ICD-9-CM
365.59	Glaucoma associated with other lens disorders	Diagnosis	ICD-9-CM
365.6	Glaucoma associated with other ocular disorders	Diagnosis	ICD-9-CM
365.60	Glaucoma associated with unspecified ocular disorder	Diagnosis	ICD-9-CM
365.61	Glaucoma associated with pupillary block	Diagnosis	ICD-9-CM
365.62	Glaucoma associated with ocular inflammations	Diagnosis	ICD-9-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
365.63	Glaucoma associated with vascular disorders of eye	Diagnosis	ICD-9-CM
365.64	Glaucoma associated with tumors or cysts	Diagnosis	ICD-9-CM
365.65	Glaucoma associated with ocular trauma	Diagnosis	ICD-9-CM
365.7	Glaucoma stage	Diagnosis	ICD-9-CM
365.70	Glaucoma stage, unspecified	Diagnosis	ICD-9-CM
365.71	Mild stage glaucoma	Diagnosis	ICD-9-CM
365.72	Moderate stage glaucoma	Diagnosis	ICD-9-CM
365.73	Severe stage glaucoma	Diagnosis	ICD-9-CM
365.74	Indeterminate stage glaucoma	Diagnosis	ICD-9-CM
365.8	Other specified forms of glaucoma	Diagnosis	ICD-9-CM
365.81	Hypersecretion glaucoma	Diagnosis	ICD-9-CM
365.82	Glaucoma with increased episcleral venous pressure	Diagnosis	ICD-9-CM
365.83	Aqueous misdirection	Diagnosis	ICD-9-CM
365.89	Other specified glaucoma	Diagnosis	ICD-9-CM
365.9	Unspecified glaucoma	Diagnosis	ICD-9-CM
66761	Iridotomy/iridectomy by laser surgery (eg, for glaucoma) (per session)	Procedure	CPT-4
H40.001	Preglaucoma, unspecified, right eye	Diagnosis	ICD-10-CM
H40.002	Preglaucoma, unspecified, left eye	Diagnosis	ICD-10-CM
H40.003	Preglaucoma, unspecified, bilateral	Diagnosis	ICD-10-CM
H40.009	Preglaucoma, unspecified, unspecified eye	Diagnosis	ICD-10-CM
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM
H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CM
H40.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CM
H40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CM
H40.031	Anatomical narrow angle, right eye	Diagnosis	ICD-10-CM
H40.032	Anatomical narrow angle, left eye	Diagnosis	ICD-10-CM
H40.033	Anatomical narrow angle, bilateral	Diagnosis	ICD-10-CM
H40.039	Anatomical narrow angle, unspecified eye	Diagnosis	ICD-10-CM
H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM
H40.061	Primary angle closure without glaucoma damage, right eye	Diagnosis	ICD-10-CM
H40.062	Primary angle closure without glaucoma damage, left eye	Diagnosis	ICD-10-CM
H40.063	Primary angle closure without glaucoma damage, bilateral	Diagnosis	ICD-10-CM
H40.069	Primary angle closure without glaucoma damage, unspecified eye	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1222	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1310	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1312	Pigmentary glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1313	Pigmentary glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1410	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1420	Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1430	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.1492	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1494	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.152	Residual stage of open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.20X0	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.20X1	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.20X2	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X4	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.213	Acute angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2210	Chronic angle-closure glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM
H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.50X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.50X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.50X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.50X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.50X4	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.51X0	Glaucoma secondary to other eye disorders, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage	Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage	Diagnosis	ICD-10-CM
H40.51X4	Glaucoma secondary to other eye disorders, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.52X0	Glaucoma secondary to other eye disorders, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage	Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage	Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, stage unspecified	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.60X2	Glaucoma secondary to drugs, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM
H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.812	Glaucoma with increased episcleral venous pressure, left eye	Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral	Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye	Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye	Diagnosis	ICD-10-CM
H40.822	Hypersecretion glaucoma, left eye	Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM
Cataract			
0289T	Corneal incisions in the donor cornea created using a laser, in preparation for penetrating or	Procedure	CPT-3
0290T	Corneal incisions in the recipient cornea created using a laser, in preparation for penetrating	Procedure	CPT-3
085J3ZZ	Destruction of Right Lens, Percutaneous Approach	Procedure	ICD-10-PCS
085K3ZZ	Destruction of Left Lens, Percutaneous Approach	Procedure	ICD-10-PCS
08BJ3ZZ	Excision of Right Lens, Percutaneous Approach	Procedure	ICD-10-PCS
08BK3ZZ	Excision of Left Lens, Percutaneous Approach	Procedure	ICD-10-PCS
08DJ3ZZ	Extraction of Right Lens, Percutaneous Approach	Procedure	ICD-10-PCS
08DK3ZZ	Extraction of Left Lens, Percutaneous Approach	Procedure	ICD-10-PCS
13.41	Phacoemulsification and aspiration of cataract	Procedure	ICD-9-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
13.42	Mechanical phacofragmentation and aspiration of cataract by posterior route	Procedure	ICD-9-CM
13.43	Mechanical phacofragmentation and other aspiration of cataract	Procedure	ICD-9-CM
13.64	Discission of secondary membrane (after cataract)	Procedure	ICD-9-CM
13.65	Excision of secondary membrane (after cataract)	Procedure	ICD-9-CM
13.66	Mechanical fragmentation of secondary membrane (after cataract)	Procedure	ICD-9-CM
13.69	Other cataract extraction	Procedure	ICD-9-CM
30630	Repair nasal septal perforations	Procedure	CPT-4
366	Cataract	Diagnosis	ICD-9-CM
366.00	Unspecified nonsenile cataract	Diagnosis	ICD-9-CM
366.01	Anterior subcapsular polar cataract, nonsenile	Diagnosis	ICD-9-CM
366.02	Posterior subcapsular polar cataract, nonsenile	Diagnosis	ICD-9-CM
366.03	Cortical, lamellar, or zonular cataract, nonsenile	Diagnosis	ICD-9-CM
366.04	Nuclear cataract, nonsenile	Diagnosis	ICD-9-CM
366.09	Other and combined forms of nonsenile cataract	Diagnosis	ICD-9-CM
366.1	Senile cataract	Diagnosis	ICD-9-CM
366.10	Unspecified senile cataract	Diagnosis	ICD-9-CM
366.11	Pseudoexfoliation of lens capsule	Diagnosis	ICD-9-CM
366.12	Incipient cataract	Diagnosis	ICD-9-CM
366.13	Anterior subcapsular polar senile cataract	Diagnosis	ICD-9-CM
366.14	Posterior subcapsular polar senile cataract	Diagnosis	ICD-9-CM
366.15	Cortical senile cataract	Diagnosis	ICD-9-CM
366.16	Nuclear sclerosis	Diagnosis	ICD-9-CM
366.17	Total or mature senile cataract	Diagnosis	ICD-9-CM
366.18	Hypermature senile cataract	Diagnosis	ICD-9-CM
366.19	Other and combined forms of senile cataract	Diagnosis	ICD-9-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
366.2	Traumatic cataract	Diagnosis	ICD-9-CM
366.20	Unspecified traumatic cataract	Diagnosis	ICD-9-CM
366.21	Localized traumatic opacities of cataract	Diagnosis	ICD-9-CM
366.22	Total traumatic cataract	Diagnosis	ICD-9-CM
366.23	Partially resolved traumatic cataract	Diagnosis	ICD-9-CM
366.3	Cataract secondary to ocular disorders	Diagnosis	ICD-9-CM
366.30	Unspecified cataracta complicata	Diagnosis	ICD-9-CM
366.31	Cataract secondary to glaucomatous flecks (subcapsular)	Diagnosis	ICD-9-CM
366.32	Cataract in inflammatory ocular disorders	Diagnosis	ICD-9-CM
366.33	Cataract with ocular neovascularization	Diagnosis	ICD-9-CM
366.34	Cataract in degenerative ocular disorders	Diagnosis	ICD-9-CM
366.4	Cataract associated with other disorders	Diagnosis	ICD-9-CM
366.50	Unspecified after-cataract	Diagnosis	ICD-9-CM
366.52	Other after-cataract, not obscuring vision	Diagnosis	ICD-9-CM
366.53	After-cataract, obscuring vision	Diagnosis	ICD-9-CM
366.8	Other cataract	Diagnosis	ICD-9-CM
366.9	Unspecified cataract	Diagnosis	ICD-9-CM
368	Visual disturbances	Diagnosis	ICD-9-CM
368.11	Sudden visual loss	Diagnosis	ICD-9-CM
368.12	Transient visual loss	Diagnosis	ICD-9-CM
368.8	Other specified visual disturbances	Diagnosis	ICD-9-CM
368.9	Unspecified visual disturbance	Diagnosis	ICD-9-CM
478.19	Other diseases of nasal cavity and sinuses	Diagnosis	ICD-9-CM
65710	Keratoplasty (corneal transplant); anterior lamellar	Procedure	CPT-4
65720	Keratoplasty (corneal Transplant), Lamellar	Procedure	CPT-4

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
65725	Keratoplasty (corneal Transplant), Lamellar	Procedure	CPT-4
65730	Keratoplasty (corneal transplant); penetrating (except in aphakia or pseudophakia)	Procedure	CPT-4
65740	Keratoplasty (corneal Transplant), Penetrating (except In	Procedure	CPT-4
65745	Keratoplasty (corneal Transplant), Penetrating (except In	Procedure	CPT-4
65750	Keratoplasty (corneal transplant); penetrating (in aphakia)	Procedure	CPT-4
65755	Keratoplasty (corneal transplant); penetrating (in pseudophakia)	Procedure	CPT-4
65756	Keratoplasty (corneal transplant); endothelial	Procedure	CPT-4
65767	Epikeratoplasty	Procedure	CPT-4
65855	Trabeculoplasty by laser surgery	Procedure	CPT-4
65860	Severing adhesions of anterior segment, laser technique (separate procedure)	Procedure	CPT-4
66820	Discission of secondary membranous cataract (opacified posterior lens capsule and/or	Procedure	CPT-4
66821	Discission of secondary membranous cataract (opacified posterior lens capsule and/or	Procedure	CPT-4
66825	Repositioning of intraocular lens prosthesis, requiring an incision (separate procedure)	Procedure	CPT-4
66830	Removal of secondary membranous cataract (opacified posterior lens capsule and/or anterior	Procedure	CPT-4
66840	Removal of lens material; aspiration technique, 1 or more stages	Procedure	CPT-4
66850	Removal of lens material; phacofragmentation technique (mechanical or ultrasonic) (eg,	Procedure	CPT-4
66852	Removal of lens material; pars plana approach, with or without vitrectomy	Procedure	CPT-4
66920	Removal of lens material; intracapsular	Procedure	CPT-4
66930	Removal of lens material; intracapsular, for dislocated lens	Procedure	CPT-4
66940	Removal of lens material; extracapsular (other than 66840, 66850, 66852)	Procedure	CPT-4
66982	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage	Procedure	CPT-4
66983	Intracapsular cataract extraction with insertion of intraocular lens prosthesis (1 stage procedur	Procedure	CPT-4
66984	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage	Procedure	CPT-4
748.1	Other congenital anomaly of nose	Diagnosis	ICD-9-CM
H25.011	Cortical age-related cataract, right eye	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H25.012	Cortical age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.013	Cortical age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.019	Cortical age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.031	Anterior subcapsular polar age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.032	Anterior subcapsular polar age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.033	Anterior subcapsular polar age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.039	Anterior subcapsular polar age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.041	Posterior subcapsular polar age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.042	Posterior subcapsular polar age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.043	Posterior subcapsular polar age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.049	Posterior subcapsular polar age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.091	Other age-related incipient cataract, right eye	Diagnosis	ICD-10-CM
H25.092	Other age-related incipient cataract, left eye	Diagnosis	ICD-10-CM
H25.093	Other age-related incipient cataract, bilateral	Diagnosis	ICD-10-CM
H25.099	Other age-related incipient cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.10	Age-related nuclear cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.11	Age-related nuclear cataract, right eye	Diagnosis	ICD-10-CM
H25.12	Age-related nuclear cataract, left eye	Diagnosis	ICD-10-CM
H25.13	Age-related nuclear cataract, bilateral	Diagnosis	ICD-10-CM
H25.20	Age-related cataract, morgagnian type, unspecified eye	Diagnosis	ICD-10-CM
H25.21	Age-related cataract, morgagnian type, right eye	Diagnosis	ICD-10-CM
H25.22	Age-related cataract, morgagnian type, left eye	Diagnosis	ICD-10-CM
H25.23	Age-related cataract, morgagnian type, bilateral	Diagnosis	ICD-10-CM
H25.811	Combined forms of age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.812	Combined forms of age-related cataract, left eye	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H25.813	Combined forms of age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.819	Combined forms of age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.89	Other age-related cataract	Diagnosis	ICD-10-CM
H25.9	Unspecified age-related cataract	Diagnosis	ICD-10-CM
H26.001	Unspecified infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.002	Unspecified infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.003	Unspecified infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.009	Unspecified infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.011	Infantile and juvenile cortical, lamellar, or zonular cataract, right eye	Diagnosis	ICD-10-CM
H26.012	Infantile and juvenile cortical, lamellar, or zonular cataract, left eye	Diagnosis	ICD-10-CM
H26.013	Infantile and juvenile cortical, lamellar, or zonular cataract, bilateral	Diagnosis	ICD-10-CM
H26.019	Infantile and juvenile cortical, lamellar, or zonular cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.031	Infantile and juvenile nuclear cataract, right eye	Diagnosis	ICD-10-CM
H26.032	Infantile and juvenile nuclear cataract, left eye	Diagnosis	ICD-10-CM
H26.033	Infantile and juvenile nuclear cataract, bilateral	Diagnosis	ICD-10-CM
H26.039	Infantile and juvenile nuclear cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.041	Anterior subcapsular polar infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.042	Anterior subcapsular polar infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.043	Anterior subcapsular polar infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.049	Anterior subcapsular polar infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.051	Posterior subcapsular polar infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.052	Posterior subcapsular polar infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.053	Posterior subcapsular polar infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.059	Posterior subcapsular polar infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.061	Combined forms of infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H26.062	Combined forms of infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.063	Combined forms of infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.069	Combined forms of infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.09	Other infantile and juvenile cataract	Diagnosis	ICD-10-CM
H26.101	Unspecified traumatic cataract, right eye	Diagnosis	ICD-10-CM
H26.102	Unspecified traumatic cataract, left eye	Diagnosis	ICD-10-CM
H26.103	Unspecified traumatic cataract, bilateral	Diagnosis	ICD-10-CM
H26.109	Unspecified traumatic cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.111	Localized traumatic opacities, right eye	Diagnosis	ICD-10-CM
H26.112	Localized traumatic opacities, left eye	Diagnosis	ICD-10-CM
H26.113	Localized traumatic opacities, bilateral	Diagnosis	ICD-10-CM
H26.119	Localized traumatic opacities, unspecified eye	Diagnosis	ICD-10-CM
H26.121	Partially resolved traumatic cataract, right eye	Diagnosis	ICD-10-CM
H26.122	Partially resolved traumatic cataract, left eye	Diagnosis	ICD-10-CM
H26.123	Partially resolved traumatic cataract, bilateral	Diagnosis	ICD-10-CM
H26.129	Partially resolved traumatic cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.131	Total traumatic cataract, right eye	Diagnosis	ICD-10-CM
H26.132	Total traumatic cataract, left eye	Diagnosis	ICD-10-CM
H26.133	Total traumatic cataract, bilateral	Diagnosis	ICD-10-CM
H26.139	Total traumatic cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.20	Unspecified complicated cataract	Diagnosis	ICD-10-CM
H26.211	Cataract with neovascularization, right eye	Diagnosis	ICD-10-CM
H26.212	Cataract with neovascularization, left eye	Diagnosis	ICD-10-CM
H26.213	Cataract with neovascularization, bilateral	Diagnosis	ICD-10-CM
H26.219	Cataract with neovascularization, unspecified eye	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H26.221	Cataract secondary to ocular disorders (degenerative) (inflammatory), right eye	Diagnosis	ICD-10-CM
H26.222	Cataract secondary to ocular disorders (degenerative) (inflammatory), left eye	Diagnosis	ICD-10-CM
H26.223	Cataract secondary to ocular disorders (degenerative) (inflammatory), bilateral	Diagnosis	ICD-10-CM
H26.229	Cataract secondary to ocular disorders (degenerative) (inflammatory), unspecified eye	Diagnosis	ICD-10-CM
H26.231	Glaucomatous flecks (subcapsular), right eye	Diagnosis	ICD-10-CM
H26.232	Glaucomatous flecks (subcapsular), left eye	Diagnosis	ICD-10-CM
H26.233	Glaucomatous flecks (subcapsular), bilateral	Diagnosis	ICD-10-CM
H26.239	Glaucomatous flecks (subcapsular), unspecified eye	Diagnosis	ICD-10-CM
H26.30	Drug-induced cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.31	Drug-induced cataract, right eye	Diagnosis	ICD-10-CM
H26.32	Drug-induced cataract, left eye	Diagnosis	ICD-10-CM
H26.33	Drug-induced cataract, bilateral	Diagnosis	ICD-10-CM
H26.40	Unspecified secondary cataract	Diagnosis	ICD-10-CM
H26.491	Other secondary cataract, right eye	Diagnosis	ICD-10-CM
H26.492	Other secondary cataract, left eye	Diagnosis	ICD-10-CM
H26.493	Other secondary cataract, bilateral	Diagnosis	ICD-10-CM
H26.499	Other secondary cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.8	Other specified cataract	Diagnosis	ICD-10-CM
H26.9	Unspecified cataract	Diagnosis	ICD-10-CM
H28	Cataract in diseases classified elsewhere	Diagnosis	ICD-10-CM
H53.041	Amblyopia suspect, right eye	Diagnosis	ICD-10-CM
H53.042	Amblyopia suspect, left eye	Diagnosis	ICD-10-CM
H53.043	Amblyopia suspect, bilateral	Diagnosis	ICD-10-CM
H53.049	Amblyopia suspect, unspecified eye	Diagnosis	ICD-10-CM
H53.121	Transient visual loss, right eye	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H53.122	Transient visual loss, left eye	Diagnosis	ICD-10-CM
H53.123	Transient visual loss, bilateral	Diagnosis	ICD-10-CM
H53.129	Transient visual loss, unspecified eye	Diagnosis	ICD-10-CM
H53.131	Sudden visual loss, right eye	Diagnosis	ICD-10-CM
H53.132	Sudden visual loss, left eye	Diagnosis	ICD-10-CM
H53.133	Sudden visual loss, bilateral	Diagnosis	ICD-10-CM
H53.139	Sudden visual loss, unspecified eye	Diagnosis	ICD-10-CM
H53.71	Glare sensitivity	Diagnosis	ICD-10-CM
H53.72	Impaired contrast sensitivity	Diagnosis	ICD-10-CM
H53.8	Other visual disturbances	Diagnosis	ICD-10-CM
H53.9	Unspecified visual disturbance	Diagnosis	ICD-10-CM
J34.89	Other specified disorders of nose and nasal sinuses	Diagnosis	ICD-10-CM
Q30.3	Congenital perforated nasal septum	Diagnosis	ICD-10-CM

Appendix F. Generic and Brand Names of Medical Products Used to Define Exclusion Criteria in this Request

Generic Name	Brand Name
Propel	
mometasone furoate 0.37 MG	Propel
Sinuva	
mometasone furoate	Sinuva
Glaucoma	
acetylcholine chloride	Miochol-E
apraclonidine HCl	lopidine
apraclonidine HCl	apraclonidine
betaxolol HCl	Betoptic S
betaxolol HCl	betaxolol
bimatoprost	Lumigan
bimatoprost	bimatoprost
bimatoprost	bimatoprost (bulk)
brimonidine tartrate	Alphagan P
brimonidine tartrate	brimonidine
brimonidine tartrate/dorzolamide HCl/PF	brimonidine-dorzolamide (PF)
brimonidine tartrate/timolol maleate	Combigan
brinzolamide	Azopt
brinzolamide/brimonidine tartrate	Simbrinza
carbachol	Miostat
carbachol	carbachol (bulk)
carteolol HCl	carteolol
dapiprazole HCl	dapiprazole (bulk)
demecarium bromide	demecarium bromide (bulk)
dorzolamide HCl	Trusopt
dorzolamide HCl	dorzolamide
dorzolamide HCl/PF	dorzolamide (PF)
dorzolamide HCl/timolol maleate	Cosopt
dorzolamide HCl/timolol maleate	dorzolamide-timolol
dorzolamide HCl/timolol maleate/PF	Cosopt (PF)
dorzolamide HCl/timolol maleate/PF	dorzolamide-timolol (PF)
echothiophate iodide	Phospholine Iodide
latanoprost	Xalatan
latanoprost	Xelpros
latanoprost	latanoprost
latanoprost	latanoprost (bulk)
latanoprost/PF	latanoprost (PF)
latanoprostene bunod	Vyzulta
levobunolol HCl	Betagan
levobunolol HCl	levobunolol
metipranolol	metipranolol
netarsudil mesylate	Rhopressa
netarsudil mesylate/latanoprost	Rocklatan
pilocarpine HCl	Isopto Carpine
pilocarpine HCl	pilocarpine HCl

Appendix F. Generic and Brand Names of Medical Products Used to Define Exclusion Criteria in this Request

Generic Name	Brand Name
Glaucoma	
tafluprost/PF	Zioptan (PF)
timolol	Betimol
timolol malea/brimonidine tar/dorzolamide	timol-brimon-dorzo-latanop
HCl/latanoprost/PF	(PF)
timolol maleate	Istalol
timolol maleate	Timoptic
timolol maleate	Timoptic-XE
timolol maleate	timolol maleate
timolol maleate/PF	Timoptic Ocudose (PF)
timolol maleate/brimonidine tartrate/dorzolamide	timolol-brimonidi-dorzolam
HCl/PF	(PF)
timolol maleate/dorzolamide HCl/latanoprost/PF	timolol-dorzolamid-latanop
	(PF)
timolol maleate/latanoprost/preservative free	timolol-latanoprost(PF)
travoprost	Travatan Z
travoprost (benzalkonium)	travoprost (benzalkonium)
unoprostone isopropyl	Rescula

Appendix G. Specifications Defining Parameters for this Request

In this report we examined counts of individuals who received Sinuva or Propel, both of which are mometasone furoate (MF) sinus stents, for the treatment of nasal polyps in the Sentinel Distributed Database (SDD). Additionally, we examined these individuals further on whether or not they also had a record indicating the presence of glaucoma or cataracts in the six months prior to receiving the Sinuva MF sinus stent.

Query Period: January 1, 2016 - April 30, 2021

Enrollment Requirement: 183 days

Enrollment Gap: 45 days

Coverage Requirement: Medical and Drug Coverage

Age Groups: 0-1, 2-4, 5-9, 10-14,15-18,19-21,22-44,45-64,65-74,75+ years

Results Stratified by: Age, Sex, Year

Scenario	Exposure						Inclusion/Exclusion Criteria					
	Index Exposure	Incidence w/ respect to:	Washout (Days)	Episode Gap (Days)	Minimum Episode Duration (Days)	Days Supply	Cohort Definition	Censor due to Evidence of:	Pre-Existing Conditions	Include/Exclude	Lookback Period (Days)	Include/Exclude
1	Sinuva: Single Implant	Stent procedures/National Drug Codes: Propel or Sinuva	183	0	1	1	04: Cohort includes all valid exposure episodes during the query period. Only the first valid episode's incidence is assessed using T5WASHPER	Death, disenrollment, Data Partner end date	Nasal polyp diagnosis	Include	-183, -1	No Exclude Glaucoma or Cataracts
2	Sinuva: Single Implant	Stent procedures/National Drug Codes: Propel or Sinuva	183	0	1	1	04: Cohort includes all valid exposure episodes during the query period. Only the first valid episode's incidence is assessed using T5WASHPER	Death, disenrollment, Data Partner end date	Nasal polyp diagnosis	Include	-183, -1	Exclude glaucoma

Appendix G. Specifications Defining Parameters for this Request: mder_mpl1r_wp207

Scenario	Exposure							Inclusion/Exclusion Criteria				
	Index Exposure	Incidence w/ respect to:	Washout (Days)	Episode Gap (Days)	Minimum Episode Duration (Days)	Days Supply	Cohort Definition	Censor due to Evidence of:	Pre-Existing Conditions	Include/Exclude	Lookback Period (Days)	Include/Exclude
3	Sinuva: Single Implant	Stent procedures/National Drug Codes: Propel or Sinuva	183	0	1	1	04: Cohort includes all valid exposure episodes during the query period. Only the first valid episode's incidence is assessed using T5WASHPER	Death, disenrollment, Data Partner end date	Nasal polyp diagnosis	Include	-183, -1	Exclude cataract
4	Sinuva: Single Implant	Stent procedures: Sinuva	183	0	1	1	04: Cohort includes all valid exposure episodes during the query period. Only the first valid episode's incidence is assessed using T5WASHPER	Death, disenrollment, Data Partner end date	Nasal polyp diagnosis	Include	-183, -1	No Exclude
5	Sinuva: Single Implant	Stent procedures: Sinuva	183	0	1	1	04: Cohort includes all valid exposure episodes during the query period. Only the first valid episode's incidence is assessed using T5WASHPER	Death, disenrollment, Data Partner end date	Nasal polyp diagnosis	Include	-183, -1	Exclude glaucoma

Appendix G. Specifications Defining Parameters for this Request: mder_mpl1r_wp207

Scenario	Exposure						Inclusion/Exclusion Criteria					
	Index Exposure	Incidence w/ respect to:	Washout (Days)	Episode Gap (Days)	Minimum Episode Duration (Days)	Days Supply	Cohort Definition	Censor due to Evidence of:	Pre-Existing Conditions	Include/Exclude	Lookback Period (Days)	Include/Exclude
5	Sinuva: Single Implant	Stent procedures: Sinuva	183	0	1	1	04: Cohort includes all valid exposure episodes during the query period. Only the first valid episode's incidence is assessed using T5WASHPER	Death, disenrollment, Data Partner end date	Nasal polyp diagnosis	Include	-183, -1	Exclude glaucoma
6	Sinuva: Single Implant	Stent procedures: Sinuva	183	0	1	1	04: Cohort includes all valid exposure episodes during the query period. Only the first valid episode's incidence is assessed using T5WASHPER	Death, disenrollment, Data Partner end date	Nasal polyp diagnosis	Include	-183, -1	Exclude cataract
7	Sinuva: Repeat Implant (1 day supply, 0 days allowed gap)	--	--	0	1	1	04: Cohort includes all valid exposure episodes during the query period. Only the first valid episode's incidence is assessed using T5WASHPER	Death, disenrollment, Data Partner end date	Nasal polyp diagnosis	Include	-183, -1	No Exclude

Appendix G. Specifications Defining Parameters for this Request: mder_mpl1r_wp207

Scenario	Exposure							Inclusion/Exclusion Criteria				
	Index Exposure	Incidence w/ respect to:	Washout (Days)	Episode Gap (Days)	Minimum Episode Duration (Days)	Days Supply	Cohort Definition	Censor due to Evidence of:	Pre-Existing Conditions	Include/Exclude	Lookback Period (Days)	Include/Exclude
8	Propel: Single Implant	Stent procedures: Propel or Sinuva	183	0	1	1	04: Cohort includes all valid exposure episodes during the query period. Only the first valid episode's incidence is assessed using T5WASHPER	Death, disenrollment, Data Partner end date	Nasal polyp diagnosis	Include	-183, -1	No Exclude

International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), Healthcare Common Procedure Coding System, Level II (HCPCS), and Current Procedural Terminology codes are provided by Optum360. National Drug Codes are checked against First Data Bank's "FDB MedKnowledge®"